Christine Mikail Cvijic Sells 739 Shares of Neurogene (NASDAQ:NGNE) Stock

Neurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic sold 739 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $34.06, for a total value of $25,170.34. Following the sale, the chief financial officer owned 92,901 shares in the company, valued at $3,164,208.06. The trade was a 0.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Mikail Cvijic also recently made the following trade(s):

• On Thursday, July 2nd, Christine Mikail Cvijic sold 4,061 shares of Neurogene stock. The shares were sold at an average price of $34.82, for a total value of $141,404.02.
• On Wednesday, May 6th, Christine Mikail Cvijic sold 9,600 shares of Neurogene stock. The stock was sold at an average price of $31.25, for a total value of $300,000.00.

Neurogene Stock Up 4.3%

NASDAQ NGNE traded up $1.46 during trading hours on Thursday, hitting $35.34. The company had a trading volume of 363,205 shares, compared to its average volume of 174,652. The firm has a market cap of $558.37 million, a P/E ratio of -7.77 and a beta of 1.68. Neurogene Inc. has a fifty-two week low of $15.93 and a fifty-two week high of $37.27. The business has a fifty day simple moving average of $29.05 and a 200-day simple moving average of $23.14.

Neurogene (NASDAQ:NGNE) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.09). Equities analysts forecast that Neurogene Inc. will post -5.63 EPS for the current fiscal year.

Institutional Trading of Neurogene

A number of institutional investors have recently made changes to their positions in the stock. Jennison Associates LLC boosted its stake in Neurogene by 35.3% during the 4th quarter. Jennison Associates LLC now owns 533,088 shares of the company’s stock valued at $10,982,000 after purchasing an additional 138,999 shares in the last quarter. ArrowMark Colorado Holdings LLC raised its stake in shares of Neurogene by 1.8% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 595,839 shares of the company’s stock worth $10,326,000 after buying an additional 10,442 shares in the last quarter. Blair William & Co. IL lifted its holdings in shares of Neurogene by 6.4% in the third quarter. Blair William & Co. IL now owns 141,820 shares of the company’s stock valued at $2,458,000 after buying an additional 8,584 shares during the period. PNC Financial Services Group Inc. lifted its holdings in shares of Neurogene by 24.7% in the third quarter. PNC Financial Services Group Inc. now owns 5,055 shares of the company’s stock valued at $88,000 after buying an additional 1,000 shares during the period. Finally, Wells Fargo & Company MN boosted its stake in Neurogene by 45.2% during the fourth quarter. Wells Fargo & Company MN now owns 11,037 shares of the company’s stock valued at $227,000 after buying an additional 3,438 shares in the last quarter. 52.37% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have commented on NGNE. HC Wainwright restated a “buy” rating and issued a $70.00 target price on shares of Neurogene in a research report on Tuesday, June 9th. Canaccord Genuity Group reduced their price objective on Neurogene to $180.00 and set a “buy” rating for the company in a research report on Monday, April 6th. Rodman & Renshaw initiated coverage on Neurogene in a report on Wednesday, June 3rd. They issued a “buy” rating and a $70.00 price objective for the company. UBS Group set a $70.00 target price on Neurogene in a research report on Wednesday, June 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Neurogene in a research note on Tuesday, April 21st. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Neurogene presently has an average rating of “Buy” and a consensus price target of $84.83.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.